HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Corina Borghouts Selected Research

Neoplasms (Cancer)

8/2013The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells.
7/2012Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.
6/2012Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells.
6/2012Stat3 is activated in skin lesions by the local application of imiquimod, a ligand of TLR7, and inhibited by the recombinant peptide aptamer rS3-PA.
1/2012A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells.
4/2010The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.
1/2010Visualization of Stat3 and Stat5 transactivation activity with specific response element dependent reporter constructs integrated into lentiviral gene transfer vectors.
2/2008Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.
12/2006Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
11/2005Current strategies for the development of peptide-based anti-cancer therapeutics.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Corina Borghouts Research Topics

Disease

11Neoplasms (Cancer)
08/2013 - 06/2005
3Breast Neoplasms (Breast Cancer)
08/2013 - 12/2006
2Glioblastoma (Glioblastoma Multiforme)
07/2012 - 02/2008
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2015
1Hematologic Neoplasms (Hematological Malignancy)
03/2015
1Colorectal Neoplasms (Colorectal Cancer)
06/2012
1Psoriasis (Pustulosis Palmaris et Plantaris)
06/2012
1Inflammation (Inflammations)
01/2010
1Genomic Instability
02/2004

Drug/Important Bio-Agent (IBA)

8Peptides (Polypeptides)IBA
08/2013 - 11/2005
5Proteins (Proteins, Gene)FDA Link
08/2013 - 02/2004
3Peptide AptamersIBA
02/2008 - 06/2005
2Phosphotransferases (Kinase)IBA
03/2015 - 12/2006
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2013 - 06/2012
2DNA (Deoxyribonucleic Acid)IBA
08/2013 - 06/2012
2LigandsIBA
08/2013 - 01/2010
2Transcription Factors (Transcription Factor)IBA
08/2013 - 04/2010
2CytokinesIBA
08/2013 - 06/2012
2Small Interfering RNA (siRNA)IBA
08/2013 - 07/2012
1STAT5 Transcription FactorIBA
08/2013
1Recombinant ProteinsIBA
08/2013
1Recombinant Fusion ProteinsIBA
07/2012
1SurvivinIBA
07/2012
1ApoferritinsIBA
07/2012
1ThioredoxinsIBA
07/2012
1Cytotoxins (Cytolysins)IBA
06/2012
1Topoisomerase I InhibitorsIBA
06/2012
1Irinotecan (Camptosar)FDA LinkGeneric
06/2012
1ChemokinesIBA
06/2012
1Interleukin-6 (Interleukin 6)IBA
01/2010
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
01/2010
1ErbB Receptors (EGF Receptor)IBA
12/2006
1Insulin-Like Growth Factor I (IGF-1)IBA
12/2006
1Paclitaxel (Taxol)FDA LinkGeneric
12/2006
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2006
1Neuregulin-1 (Neuregulin 1)IBA
12/2006
1NexusIBA
02/2004

Therapy/Procedure

3Therapeutics
07/2012 - 06/2005
2Drug Therapy (Chemotherapy)
06/2012 - 12/2006
1Transplantation
07/2012